Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

× No keyword cloud information.

9 in total

1. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Authors: Markus Ditschkowski; Ahmet H Elmaagacli; Rudolf Trenschel; Tanja Gromke; Nina K Steckel; Michael Koldehoff; Dietrich W Beelen
Journal: Haematologica Date: 2012-04-04 Impact factor: 9.941

Review 2. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors: Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal: Blood Date: 2012-06-14 Impact factor: 22.113

Review 3. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Authors: Haefaa Alchalby; Nicolaus Kröger
Journal: Curr Hematol Malig Rep Date: 2010-04 Impact factor: 3.952

Review 4. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

Authors: V Fauble; J Leis; R A Mesa
Journal: Leuk Suppl Date: 2012-05-09

5. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

Authors: Bart L Scott; Ted A Gooley; Mohamed L Sorror; Andrew R Rezvani; Michael L Linenberger; Jonathan Grim; Brenda M Sandmaier; David Myerson; Thomas R Chauncey; Rainer Storb; Veronika Buxhofer-Ausch; Jerald P Radich; Frederick R Appelbaum; H Joachim Deeg
Journal: Blood Date: 2012-01-10 Impact factor: 22.113

6. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Authors: David S Snyder; Joycelynne Palmer; Karl Gaal; Anthony S Stein; Vinod Pullarkat; Firoozeh Sahebi; Nyana Vora; Ryotaro Nakamura; Stephen J Forman
Journal: Biol Blood Marrow Transplant Date: 2009-09-26 Impact factor: 5.742

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

1. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Review 2. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Review 3. Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Review 4. Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

5. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

6. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Review 7. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.

8. State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

Review 9. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.